Advanced Human Imaging (AHI) AI Stock Analysis

• Market Cap: AU$20.52M
• Dividend Yield: N/A
• Average Volume (3M): 0.00
• Price to Earnings (P/E): ―
• Beta (1Y): -1.52
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: AU
• Employees: 19
• Sector: Technology
• Sector Strength: 88
• Industry: Software - Application
• EPS (TTM): -0.02
• Shares Outstanding: 280,582,280
• 10 Day Avg. Volume: 0
• 30 Day Avg. Volume: 0
• PEG Ratio: 0.06
• Price to Book (P/B): 19.14
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -5.22
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 37 Underperform
• Price Target: ―

The overall stock score for Advanced Human Imaging Ltd. is 37, reflecting significant financial weaknesses and valuation concerns. The company's persistent financial losses, high leverage, and negative cash flow position are major detractors. Additionally, the technical analysis shows bearish signals, with an overbought RSI suggesting potential price corrections. Despite a stable share price, the lack of profitability and dividend yield further weaken the stock's appeal.

Advanced Human Imaging Business Overview & Revenue Model

Company Description

Advanced Human Imaging Ltd. (AHI) is a technology company specializing in mobile application-based human imaging solutions. The company operates in the digital health sector, offering advanced body measurement and biometric tracking capabilities through its proprietary technology. AHI's core products leverage smartphone cameras and artificial intelligence to provide users with detailed health and wellness insights, facilitating better personal health management and clinical assessments.

How the Company Makes Money

Advanced Human Imaging Ltd. generates revenue through a combination of licensing its technology, subscription services, and strategic partnerships. The company's primary revenue streams include licensing fees from integrating its imaging solutions into third-party applications and direct consumer subscriptions for its health and wellness applications. Additionally, AHI collaborates with health organizations, fitness companies, and insurers, which further contributes to its earnings through joint ventures and co-branded products. These partnerships allow AHI to expand its market reach and enhance product offerings, providing value to both users and partners.

Advanced Human Imaging Financial Statement Overview

Summary

Advanced Human Imaging Ltd. shows substantial financial challenges, with negative profitability, high leverage, and cash flow difficulties across all financial statements. The income statement reflects persistent losses, the balance sheet indicates high debt levels relative to equity, and cash flow analysis shows inadequate cash generation from operations. These suggest significant financial distress, necessitating strategic improvements in revenue generation, cost management, and capital structure.

Income Statement

The company's income statement shows a troubling trend, with consistently negative gross profit margins and net income. The gross profit margin is negative due to costs exceeding revenue, and the net profit margin has been consistently negative as well. While there is revenue growth from the previous year, it is not sufficient to cover the losses or improve profitability. EBIT and EBITDA margins are also negative, indicating operational inefficiencies. Overall, the income statement reflects poor financial health and a need for significant improvement in revenue generation and cost management.

Balance Sheet

The balance sheet reveals a highly leveraged position with a debt-to-equity ratio that suggests substantial reliance on debt financing. The equity ratio is low, indicating that a smaller portion of the company's assets is financed by the owners. Return on equity is negative due to ongoing losses, further highlighting financial instability. While the company does have assets, the high level of liabilities poses risks to financial health and sustainability. The balance sheet reflects a need for better capital management and reduction of liabilities.

Cash Flow

Cash flow analysis shows negative operating cash flows, indicating the company is not generating enough cash from its core operations to sustain itself. The free cash flow is also negative, exacerbating concerns about liquidity and financial flexibility. The operating cash flow to net income ratio is unfavorable, as is the free cash flow to net income ratio, highlighting cash inefficiencies and the inability to convert earnings into cash. Despite inflows from financing activities, the overall cash flow position remains weak.

Breakdown	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	2.68M	654.84K	257.60K	593.35K	139.86K
Gross Profit	-3.72M	-4.67M	-3.17M	-9.29M	-3.76M
EBITDA	-3.10M	-12.04M	-19.55M	-14.80M	-6.09M
Net Income	-4.15M	-12.83M	-20.08M	-14.06M	-5.40M
Balance Sheet
Total Assets	15.20M	8.91M	10.66M	5.42M	2.95M
Cash, Cash Equivalents and Short-Term Investments	25.76K	2.10M	6.01M	2.17M	627.30K
Total Debt	2.44M	1.80M	1.16M	2.32M	1.39M
Total Liabilities	11.92M	6.88M	2.11M	3.44M	2.49M
Stockholders Equity	1.75M	2.03M	8.56M	1.98M	462.51K
Cash Flow
Free Cash Flow	-4.75M	-7.43M	-9.95M	-4.13M	-2.76M
Operating Cash Flow	-4.75M	-7.37M	-9.86M	-4.10M	-2.70M
Investing Cash Flow	-95.64K	-669.26K	-3.38M	-3.44M	-84.68K
Financing Cash Flow	2.78M	4.17M	17.08M	9.09M	2.84M

Advanced Human Imaging Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.08
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Neutral
• RSI: Negative
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:AHI, the sentiment is Negative. The current price of 0.08 is below the 20-day moving average (MA) of 0.08, below the 50-day MA of 0.08, and below the 200-day MA of 0.08, indicating a bearish trend. The MACD of >-0.01 indicates Neutral momentum. The RSI at 100.00 is Negative, neither overbought nor oversold. The STOCH value of -50.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:AHI.

Advanced Human Imaging Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	63 Neutral	$33.79B	5.85	-11.85%	1.81%	5.29%	-18.24%
1CG	51 Neutral	AU$10.64M	―	-86.94%	―	26.58%	32.43%
1CG	51 Neutral	AU$10.64M	―	-86.94%	―	26.58%	32.43%
AR9	50 Neutral	AU$50.62M	―	-45.31%	―	-28.80%	32.87%
AR9	50 Neutral	AU$50.62M	―	-45.31%	―	-28.80%	32.87%
PFM	47 Neutral	AU$15.19M	―	-25.95%	―	26.33%	31.67%
PFM	47 Neutral	AU$15.19M	―	-25.95%	―	26.33%	31.67%
HTG	44 Neutral	AU$13.64M	―		―	0.82%	-58.82%
HTG	44 Neutral	AU$13.64M	―		―	0.82%	-58.82%
AMX	44 Neutral	AU$20.42M	―	-24.21%	―	-11.35%	-49.13%
AMX	44 Neutral	AU$20.42M	―	-24.21%	―	-11.35%	-49.13%
AHI	37 Underperform	AU$20.52M	―	-219.41%	―	―	―

Advanced Human Imaging Corporate Events

Advanced Health Intelligence Secures Extension for R&D Claim Submission

Advanced Health Intelligence Ltd has been granted a 31-day extension by AusIndustry to finalize its FY2024 R&D reimbursement submission, allowing the company to include international R&D expenditures in its claim. This extension is crucial for AHI as it anticipates receiving approximately AUD $1.1 million, which will support its operational execution during a critical phase of commercial expansion. The company’s consistent R&D reimbursements since 2017 highlight its commitment to innovation in the med-tech sector, while its expanding patent portfolio and global R&D activities reinforce its position as a leader in digital health. Additionally, AHI is pursuing an R&D Advance Facility for AUD $750,000, which, combined with the expected reimbursement, will strengthen its cash flow position with up to AUD $1,850,000 in non-dilutive capital.